Myles Minter
Stock Analyst at William Blair
(1.38)
# 3,354
Out of 4,761 analysts
18
Total ratings
53.33%
Success rate
-6.27%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Myles Minter
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CAMP Camp4 Therapeutics | Initiates: Outperform | n/a | $4.81 | - | 1 | Nov 5, 2024 | |
| ARGX argenx SE | Upgrades: Outperform | n/a | $644.48 | - | 2 | Nov 1, 2024 | |
| KRRO Korro Bio | Initiates: Outperform | n/a | $26.29 | - | 1 | Aug 14, 2024 | |
| NMRA Neumora Therapeutics | Initiates: Outperform | n/a | $1.80 | - | 1 | Oct 10, 2023 | |
| ARCT Arcturus Therapeutics Holdings | Initiates: Outperform | $71 | $17.77 | +299.55% | 1 | Jul 24, 2023 | |
| MRNA Moderna | Initiates: Market Perform | n/a | $35.53 | - | 1 | Jul 24, 2023 | |
| VRTX Vertex Pharmaceuticals | Initiates: Outperform | n/a | $484.24 | - | 1 | May 30, 2023 | |
| PRAX Praxis Precision Medicines | Downgrades: Market Perform | n/a | $74.49 | - | 2 | Mar 6, 2023 | |
| LRMR Larimar Therapeutics | Upgrades: Outperform | n/a | $3.19 | - | 3 | Sep 19, 2022 | |
| ALNY Alnylam Pharmaceuticals | Initiates: Outperform | n/a | $250.59 | - | 1 | Jun 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $32.32 | - | 2 | Dec 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $1.87 | - | 1 | Sep 27, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $116 | $120.69 | -3.89% | 1 | Feb 24, 2020 |
Camp4 Therapeutics
Nov 5, 2024
Initiates: Outperform
Price Target: n/a
Current: $4.81
Upside: -
argenx SE
Nov 1, 2024
Upgrades: Outperform
Price Target: n/a
Current: $644.48
Upside: -
Korro Bio
Aug 14, 2024
Initiates: Outperform
Price Target: n/a
Current: $26.29
Upside: -
Neumora Therapeutics
Oct 10, 2023
Initiates: Outperform
Price Target: n/a
Current: $1.80
Upside: -
Arcturus Therapeutics Holdings
Jul 24, 2023
Initiates: Outperform
Price Target: $71
Current: $17.77
Upside: +299.55%
Moderna
Jul 24, 2023
Initiates: Market Perform
Price Target: n/a
Current: $35.53
Upside: -
Vertex Pharmaceuticals
May 30, 2023
Initiates: Outperform
Price Target: n/a
Current: $484.24
Upside: -
Praxis Precision Medicines
Mar 6, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $74.49
Upside: -
Larimar Therapeutics
Sep 19, 2022
Upgrades: Outperform
Price Target: n/a
Current: $3.19
Upside: -
Alnylam Pharmaceuticals
Jun 7, 2022
Initiates: Outperform
Price Target: n/a
Current: $250.59
Upside: -
Dec 14, 2021
Upgrades: Outperform
Price Target: n/a
Current: $32.32
Upside: -
Sep 27, 2021
Initiates: Outperform
Price Target: n/a
Current: $1.87
Upside: -
Feb 24, 2020
Initiates: Outperform
Price Target: $116
Current: $120.69
Upside: -3.89%